Replies to post #233577 on Amarin Corp Plc (AMRN)

[dmiller]

That guidance is not going to help the stock.

[sts66]

Yeah, with scrip growth of 80%+ YoY in 2019 projecting a slowdown to 60% growth in 2020 with such a widely expanded label is beyond conservative - it's nutty. There is a large pent-up demand for V and the R-IT label from patients who have docs that wouldn't prescribe it off label (or insurers wouldn't cover off label) and were waiting for the sNDA to be approved.

[Mr1979]

He is definitely sandbagging it not sure why